AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis

AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis

Though anselamimab failed its Phase 3 test in light chain amyloidosis, AstraZeneca points to encouraging results in a pre-defined patient subgroup — which may not be a winning strategy. Prothena resurrected its failed drug candidate for the disease based on a subgroup analysis, only to see that antibody fall short in a pivotal study. The post AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis appeared first on …

AstraZeneca rare disease drug fails key trial tests

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

AstraZeneca sifts for efficacy crumbs in amyloidosis trial

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup

AstraZeneca’s amyloidosis treatment fails main goal in late-stage study - Regional Media News

(Reuters) -AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of protein deposits in the body. The primary outcome of the study was being measured as a combination of how long patients with advanced, heart-related amyloidosis lived and how often they were hospitalised for cardiovascular issues, the Ang…

AstraZeneca’s AL amyloidosis drug fails to impress in Phase III

Anselaminab showed a clinically meaningful improvement in a subgroup of AL amyloidosis patients.The post AstraZeneca’s AL amyloidosis drug fails to impress in Phase III appeared first on Clinical Trials Arena.

AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup

Last year, AstraZeneca predicted that its drug for the rare disease light chain amyloidosis could have peak revenue of up to $3 billion. But after Wednesday, that forecast will surely be revised downwards following the ...